Zydus Cadila ties up with Takeda to address emerging infectious diseases

20 September, Mumbai

Pharma Major, Zydus Cadila today announced partnership with Japan’s Takeda Pharmaceutical Company Ltd to tackle chikungunya and other emerging infectious diseases. The broad-based agreement includes early stage development to the final commercialisation of the vaccine.

There is currently no vaccine to prevent or medicine to treat chikungunya virus infection, Cadila Healthcare said in a filing with BSE.

Zydus Group Chairman and MD, Pankaj R Patel, said “By partnering with Takeda on this very important research and development initiative and leveraging our development capabilities, we will be taking an all-important step to prevent the disease burden.”

Cadila Healthcare said the terms of the agreement are not disclosed, but it is expected that this partnership will boost access to medicines in the future.”

Takeda is the centre of important vaccine-related activities in global health and emerging infectious diseases.

This is another demonstration of Takeda’s major commitment to the health of children in developing countries and elsewhere around the world,” Takeda Vaccines Chief Operating Officer Rahul Singhvi said.